Inventor
CONNORS MARK
US20 patents
⚠️ This page may combine multiple inventors who share the name “CONNORS MARK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
US HEALTH
17 patentsUS5922326AJul 13, 1999
Attenuated respiratory syncytial virus vaccine compositions
US HEALTH109 citations99
US5882651AMar 16, 1999
Attenuated respiratory syncytial virus vaccine compositions
US HEALTH19 citations90
US10035844B2Jul 31, 2018
Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
US HEALTH6 citations83
US9695230B2Jul 4, 2017
Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
US HEALTH9 citations83
US9475862B2Oct 25, 2016
Neutralizing GP41 antibodies and their use
US HEALTH6 citations82
US10562960B2Feb 18, 2020
Neutralizing antibodies to gp120 and their use
US HEALTH5 citations81
US10035845B2Jul 31, 2018
Neutralizing antibodies to HIV-1 and their use
US HEALTH2 citations72
US9738703B2Aug 22, 2017
Neutralizing antibodies to HIV-1 and their use
US HEALTH2 citations72
US12202886B2Jan 21, 2025
Neutralizing antibodies to GP120 and their use
US HEALTH1 citations71
US6284254B1Sep 4, 2001
Immunogenic compositions comprising cold-adapted attenuated respiratory syncytial virus mutants
US HEALTH5 citations71
US12545719B2Feb 10, 2026
Neutralizing antibodies to GP120 and their use
US HEALTH0 citations59
US12043660B2Jul 23, 2024
10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use
US HEALTH0 citations56
US11236152B2Feb 1, 2022
Neutralizing antibodies to HIV-1 GP41 and their use
US HEALTH0 citations56
US10815295B2Oct 27, 2020
Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein
US HEALTH0 citations51
US10047148B2Aug 14, 2018
Neutralizing GP41 antibodies and their use
US HEALTH0 citations50
US9783595B2Oct 10, 2017
Neutralizing GP41 antibodies and their use
US HEALTH0 citations50
US10047147B2Aug 14, 2018
Neutralizing GP41 antibodies and their use
US HEALTH0 citations44